RespireRx Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, … Read more
RespireRx Pharmaceuticals Inc (RSPI) - Net Assets
Latest net assets as of September 2023: $-12.30 Million USD
Based on the latest financial reports, RespireRx Pharmaceuticals Inc (RSPI) has net assets worth $-12.30 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($108.66K) and total liabilities ($12.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.30 Million |
| % of Total Assets | -11316.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 223.48 |
RespireRx Pharmaceuticals Inc - Net Assets Trend (1988–2022)
This chart illustrates how RespireRx Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RespireRx Pharmaceuticals Inc (1988–2022)
The table below shows the annual net assets of RespireRx Pharmaceuticals Inc from 1988 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-11.88 Million | -18.71% |
| 2021-12-31 | $-10.01 Million | -24.11% |
| 2020-12-31 | $-8.06 Million | -8.31% |
| 2019-12-31 | $-7.44 Million | -29.85% |
| 2018-12-31 | $-5.73 Million | -31.64% |
| 2017-12-31 | $-4.36 Million | +20.72% |
| 2016-12-31 | $-5.49 Million | -91.93% |
| 2015-12-31 | $-2.86 Million | -30.08% |
| 2014-12-31 | $-2.20 Million | +47.46% |
| 2013-12-31 | $-4.19 Million | -39.97% |
| 2012-12-31 | $-2.99 Million | -542.66% |
| 2011-12-31 | $675.91K | -71.88% |
| 2010-12-31 | $2.40 Million | +257.31% |
| 2009-12-31 | $-1.53 Million | -144.98% |
| 2008-12-31 | $3.40 Million | -79.63% |
| 2007-12-31 | $16.68 Million | +100.43% |
| 2006-12-31 | $8.32 Million | -45.01% |
| 2005-12-31 | $15.13 Million | -36.01% |
| 2004-12-31 | $23.65 Million | +1764.85% |
| 2003-12-31 | $-1.42 Million | -140.09% |
| 2002-12-31 | $-591.59K | -591.84% |
| 2001-12-31 | $120.28K | 0.00% |
| 2000-12-31 | $120.28K | -94.89% |
| 1999-12-31 | $2.35 Million | +1540.84% |
| 1998-12-31 | $-163.33K | +84.16% |
| 1997-12-31 | $-1.03 Million | -115.61% |
| 1996-12-31 | $6.61 Million | +100.15% |
| 1995-12-31 | $3.30 Million | 0.00% |
| 1994-12-31 | $3.30 Million | -65.98% |
| 1993-12-31 | $9.70 Million | -23.26% |
| 1992-12-31 | $12.64 Million | +532.00% |
| 1991-12-31 | $2.00 Million | +36.99% |
| 1990-12-31 | $1.46 Million | -42.06% |
| 1989-12-31 | $2.52 Million | -49.40% |
| 1988-12-31 | $4.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RespireRx Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17343785600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $125.54K | % |
| Other Components | $164.05 Million | % |
| Total Equity | $-11.88 Million | 100.00% |
RespireRx Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of RespireRx Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ATOSS SOFTWARE - Dusseldorf Stock Exchang
DU:AOF
|
$819.77K |
|
Identillect Technologies Corp
V:ID
|
$819.87K |
|
E2Gold Inc
OTCQB:ETUGF
|
$819.94K |
|
MASI AGRICOLA S.P.A.
F:0CY
|
$820.39K |
|
Osmosun SA
PA:ALWTR
|
$818.09K |
|
TTM TECHNOLOGIES - Dusseldorf Stock Exchang
DU:TT1
|
$817.97K |
|
Digitalist Group Oyj
HE:DIGIGR
|
$817.05K |
|
CORP. FIN. ALBA
MU:CSV
|
$817.00K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RespireRx Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -10,007,758 to -11,880,320, a change of -1,872,562.
- Net loss of 2,102,720 reduced equity.
- Other factors increased equity by 230,158.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.10 Million | -17.7% |
| Other Changes | $230.16K | +1.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares RespireRx Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1988-12-31 | $8019.32 | $0.00 | x |
| 1989-12-31 | $3142.14 | $0.00 | x |
| 1990-12-31 | $1802.47 | $0.00 | x |
| 1991-12-31 | $2134.47 | $0.00 | x |
| 1992-12-31 | $12319.69 | $0.00 | x |
| 1993-12-31 | $4503.25 | $0.00 | x |
| 1994-12-31 | $1781.86 | $0.00 | x |
| 1995-12-31 | $1781.86 | $0.00 | x |
| 1996-12-31 | $2601.42 | $0.00 | x |
| 1997-12-31 | $-350.02 | $0.00 | x |
| 1998-12-31 | $-39.59 | $0.00 | x |
| 1999-12-31 | $484.22 | $0.00 | x |
| 2000-12-31 | $23.55 | $0.00 | x |
| 2001-12-31 | $23.55 | $0.00 | x |
| 2002-12-31 | $-106.75 | $0.00 | x |
| 2003-12-31 | $-273.67 | $0.00 | x |
| 2004-12-31 | $3315.11 | $0.00 | x |
| 2005-12-31 | $1505.52 | $0.00 | x |
| 2006-12-31 | $787.25 | $0.00 | x |
| 2007-12-31 | $1286.40 | $0.00 | x |
| 2008-12-31 | $232.06 | $0.00 | x |
| 2009-12-31 | $-89.01 | $0.00 | x |
| 2010-12-31 | $105.99 | $0.00 | x |
| 2011-12-31 | $27.46 | $0.00 | x |
| 2014-12-31 | $-37.10 | $0.00 | x |
| 2015-12-31 | $-24.20 | $0.00 | x |
| 2016-12-31 | $-29.47 | $0.00 | x |
| 2017-12-31 | $-18.01 | $0.00 | x |
| 2018-12-31 | $-17.11 | $0.00 | x |
| 2019-12-31 | $-19.05 | $0.00 | x |
| 2020-12-31 | $-0.31 | $0.00 | x |
| 2021-12-31 | $-0.11 | $0.00 | x |
| 2022-12-31 | $-0.11 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RespireRx Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-190.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1988 | -24.10% | -1200.00% | 0.02x | 1.03x | $-1.70 Million |
| 1989 | -87.30% | -2200.00% | 0.04x | 1.09x | $-2.45 Million |
| 1990 | -178.08% | -2600.00% | 0.06x | 1.21x | $-2.75 Million |
| 1991 | -120.00% | -240.00% | 0.35x | 1.42x | $-2.60 Million |
| 1992 | -6.33% | -30.77% | 0.20x | 1.03x | $-2.06 Million |
| 1993 | -48.45% | -4700.00% | 0.01x | 1.07x | $-5.67 Million |
| 1994 | -206.06% | -6800.00% | 0.02x | 1.48x | $-7.13 Million |
| 1995 | -206.06% | -6800.00% | 0.02x | 1.48x | $-7.13 Million |
| 1996 | -74.64% | 0.00% | 0.00x | 1.26x | $-5.59 Million |
| 1997 | 0.00% | -4044.58% | 0.05x | 0.00x | $-5.15 Million |
| 1998 | 0.00% | -51.45% | 2.03x | 0.00x | $-1.61 Million |
| 1999 | -8.39% | -3.58% | 1.58x | 1.48x | $-432.73K |
| 2000 | -2222.54% | -60.17% | 0.80x | 46.06x | $-2.69 Million |
| 2001 | -2222.54% | -60.17% | 0.80x | 46.06x | $-2.69 Million |
| 2002 | 0.00% | -15.28% | 2.16x | 0.00x | $-923.48K |
| 2003 | 0.00% | -22.46% | 2.40x | 0.00x | $-1.03 Million |
| 2004 | -25.35% | -0.09% | 233.11x | 1.26x | $-8.36 Million |
| 2005 | -76.70% | -450.28% | 0.14x | 1.19x | $-13.12 Million |
| 2006 | -192.96% | -1363.51% | 0.11x | 1.25x | $-16.89 Million |
| 2007 | -77.77% | -51876.65% | 0.00x | 1.11x | $-14.64 Million |
| 2008 | -429.70% | 0.00% | 0.00x | 1.52x | $-14.94 Million |
| 2009 | 0.00% | -76739.58% | 0.02x | 0.00x | $-8.29 Million |
| 2010 | 67.77% | 15.55% | 2.94x | 1.48x | $1.39 Million |
| 2011 | -333.60% | -72.40% | 1.71x | 2.69x | $-2.32 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-780.44K |
| 2014 | 0.00% | -4390.57% | 0.15x | 0.00x | $-2.49 Million |
| 2015 | 0.00% | -6859.37% | 0.60x | 0.00x | $-5.68 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.68 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.86 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.02 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.78 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.04 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.87 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-914.69K |
Industry Comparison
This section compares RespireRx Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RespireRx Pharmaceuticals Inc (RSPI) | $-12.30 Million | -24.10% | N/A | $819.01K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |